Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Immunome, Inc.

IMNM

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Last trade $17.19
Day change -$0.42 (-2.39%)
Day range $16.79 – $18.10
Volume 633,402
Market cap $2.08B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.08B
Price / earnings
—
Price / book
4.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.27×

Profitability

Earnings per share
-$2.39
Return on assets
-55.91%
Return on equity
-62.22%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.66×
Quick ratio
11.66×
Cash ratio
5.2×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$238.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMNM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$4.02M$2.93M$2.74M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$4.02M$2.93M$2.74M
Selling, general and administrative$20.86M$18.25M$12.95M$12.09M$10.95M$10.04M$10.69M$10.45M
Research and development$69.51M$59.89M$46.38M$60.77M$49.19M$40.45M$36.87M$75.26M
Total operating expenses$90.36M$78.14M$59.33M$72.86M$60.14M$50.49M$47.56M$85.71M
Operating income-$90.36M-$78.14M-$59.33M-$72.86M-$60.14M-$46.48M-$44.64M-$82.97M
Interest expense$0$0$0$2.96M$0$0$0$2.72M
Income before taxes-$85.78M-$73.13M-$53.84M-$69.9M-$57.46M-$43.4M-$41.7M-$80.25M
Income taxes$0$0$0$0$0$0$0$0
Net income-$85.78M-$73.13M-$53.84M-$69.9M-$57.46M-$43.4M-$41.7M-$80.25M
Net income attributable to common shareholders-$85.78M-$73.13M-$53.84M-$69.9M-$57.46M-$43.4M-$41.7M-$80.25M
EBITDA-$89.36M-$77.18M-$58.73M-$72.23M-$59.55M-$45.84M-$44.03M-$82.52M
Basic earnings per share-$0.76-$0.65-$0.48-$0.74-$0.65-$0.50-$0.52-$1.28
Diluted earnings per share-$0.76-$0.65-$0.48-$0.74-$0.65-$0.50-$0.52-$1.28

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know

Immunome Inc. (IMNM) has a mean analyst price target of $35.33, suggesting 74% upside potential from its current $20.31 price. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that price targets alone should not drive investment decisions, as analysts often set overly optimistic targets due to business incentives.

The Motley Fool

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares (30% of his direct holdings) for approximately $204,000 on April 2, 2026, through a pre-arranged Rule 10b5-1 trading plan established in December 2025. The sale represents routine financial diversification rather than a bearish signal, as Higgins maintains a substantial $480,000 direct position. The real catalyst for investors is Immunome's planned NDA submission for varegacestat in Q2 2026, following positive Phase 3 RINGSIDE trial results in December 2025.

Benzinga

Evaluating Immunome: Insights From 4 Financial Analysts

In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Immunome is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Biren Amin Piper Sandler Announces Overweight $27.00 - Brian Cheng JP Morgan Announces Overweight $24.00 - Michael Schmidt Guggenheim Announces Buy $35.00 - David Nierengarten Wedbush Raises Outperform $33.00 $27.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunome. This offers insight ...Full story available on Benzinga.com

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 19, 20071-for-1,000reverse split